UMDF Cosigns Letter to Congress Encouraging End-of-Year Rare Disease Legislative Priorities
UMDF Cosigns Letter to Congress Encouraging End-of-Year Action on Accelerating Kids’ Access to Care Act, Rare Pediatric Disease Priority Review...
Read moreLatest News -Press Room
November 2024 Newsletter: FDA News, Rare Revolution Magazine Feature, Therapeutic Pipeline Updates, and more
Sign-up to receive the UMDF newsletter via email at Newsletter Signup. In early October, an FDA Advisory Committee voted 10-6 supporting...
Read moreAdvocacy Update – Oct 2024: FDA AdComm Brings Good News, Plus DC End of Year Business
FDA Advisory Committee Deems Potential Barth Syndrome Drug “Effective” Earlier this month, an FDA Advisory Committee voted 10-6...
Read moreUMDF Reacts to FDA Advisory Committee’s Elamipretide Recommendation
After a full day of testimony that consistently demonstrated the need and efficacy of elamipretide for the treatment of Barth Syndrome, an FDA...
Read moreUMDF’s Comment to FDA’s Advisory Committee Regarding Elamipretide
Read UMDF’s Comment to FDA’s Advisory Committee regarding New Drug Application for Elamipretide in Barth...
Read moreUMDF Announces $100k Award for MEPAN Research, Bringing Total Research Grants Awarded to More Than $1 Million in the Last Year
The United Mitochondrial Disease Foundation today announced a new $100,000 grant to Madhurima Saha, PhD, of the University of Florida, for...
Read more